We are live on ! Find out more
ANIK icon

Anika Therapeutics

162 hedge funds and large institutions have $537M invested in Anika Therapeutics in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

57% more call options, than puts

Call options by funds: $2.38M | Put options by funds: $1.51M

13% more capital invested

Capital invested by funds: $474M → $537M (+$63.1M)

7% more funds holding

Funds holding: 152162 (+10)

9% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 55

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
162
Holders Change
+10
Holders Change %
+6.58%
% of All Funds
4.32%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
24
Increased
60
Reduced
55
Closed
14
Calls
$2.38M
Puts
$1.51M
Net Calls
+$864K
Net Calls Change
-$382K
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$4.7M +$577K +14,230 +16%
Principal Financial Group
27
Principal Financial Group
Iowa
$4.39M +$72.8K +1,794 +2%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$4.13M +$657K +16,200 +21%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$4.01M -$77.1K -1,900 -2%
Ameriprise
30
Ameriprise
Minnesota
$4.01M +$893K +22,008 +33%
Deutsche Bank
31
Deutsche Bank
Germany
$3.69M +$1.64M +40,537 +97%
RFC
32
Russell Frank Company
Washington
$3.62M +$687K +16,936 +26%
MOACM
33
Mutual of America Capital Management
New York
$3.21M +$20.3K +500 +0.7%
SGAM
34
Smith Group Asset Management
Texas
$3.19M +$10.1K +250 +0.4%
BWFA
35
Baltimore-Washington Financial Advisors
Maryland
$3.08M -$10.2K -251 -0.4%
Fisher Asset Management
36
Fisher Asset Management
Washington
$2.79M +$1.77M +43,595 +309%
Millennium Management
37
Millennium Management
New York
$2.7M -$4.22M -103,956 -63%
BIM
38
BlackRock Investment Management
Delaware
$2.7M +$38.6K +951 +2%
SAMC
39
Shinko Asset Management Company
Japan
$2.58M +$1.77M +43,595 +309%
AQR Capital Management
40
AQR Capital Management
Connecticut
$2.5M -$1.92M -47,453 -46%
American Century Companies
41
American Century Companies
Missouri
$2.41M +$93.1K +2,296 +4%
FIM
42
Freedom Investment Management
Connecticut
$2.23M -$240K -5,910 -11%
TCIM
43
TIAA CREF Investment Management
New York
$2.1M -$89K -2,195 -4%
RA
44
Royce & Associates
New York
$2.08M -$519K -12,800 -22%
CS
45
Credit Suisse
Switzerland
$2.04M +$884K +21,804 +91%
Nordea Investment Management
46
Nordea Investment Management
Sweden
$2.03M -$81.1K -2,000 -4%
DCM
47
Dupont Capital Management
Delaware
$1.92M -$274K -6,748 -14%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$1.9M
HFS
49
HL Financial Services
Kentucky
$1.89M +$322K +7,945 +23%
Invesco
50
Invesco
Georgia
$1.88M -$382K -9,409 -18%

ANIK Hedge Fund Activity: Q1 2016 in Review

162 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2016, worth a combined $537M — up 13% from $474M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ANIK positions and 14 closed out — a net gain of 10 holders — while 60 added to existing stakes and 55 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $7.6M. The largest seller was Portolan Capital Management, cutting an estimated $14.5M.

  • 162 institutional investors held Anika Therapeutics (ANIK) as of Q1 2016, up from 152 in Q4 2015.
  • Funds reported $537M of Anika Therapeutics stock for Q1 2016, up 13% quarter-over-quarter.
  • 24 funds opened new Anika Therapeutics positions in Q1 2016 and 14 closed out, a net change of +10 holders.
  • The largest Anika Therapeutics buyer in Q1 2016 was Renaissance Technologies, an estimated $7.6M added.
  • The largest Anika Therapeutics seller in Q1 2016 was Portolan Capital Management, an estimated $14.5M sold.

Based on aggregated 13F filings for Q1 2016.